Showing results (2031-2040 of 2,190) with videos related to
Sort By:
Pageof 219
Disease Models & Mechanisms|October 31, 2025
Establishment of a second-generation transgenic marmoset with germline transmission that models polyglutamine diseaseEiko N Minakawa, Kensuke Owari, Naotake Nogami, et al.Internal Medicine (Tokyo, Japan)|November 5, 2023
Intractable Ventricular Tachycardia Prior to an Overt Cardiac Tumor Mass of Metastatic Cardiac Rhabdomyosarcoma (Spindle-cell Type)Yosuke Terui, Hideaki Suzuki, Akio Chikata, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007Yoshihiko Segawa, Katsuyuki Kiura, Nagio Takigawa, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2020
Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged ≥75 years with squamous-cell lung cancer: TORG1322Yoshitaka Zenke, Seiji Niho, Shigeki Umemura, et al.Cancer|February 2, 2016
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trialMasayuki Takeda, Takeharu Yamanaka, Takashi Seto, et al.European Heart Journal|October 3, 2015
Genetic defects in a His-Purkinje system transcription factor, IRX3, cause lethal cardiac arrhythmiasAkiko Koizumi, Tetsuo Sasano, Wataru Kimura, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 1, 2016
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE studyK Suzuki, T Yamanaka, H Hashimoto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2018
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerThanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2015
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001Eiki Ichihara, Katsuyuki Hotta, Naoyuki Nogami, et al.Japanese Journal of Clinical Oncology|June 11, 2021
Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404Takashi Ninomiya, Naoyuki Nogami, Toshiyuki Kozuki, et al.Pageof 219